Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-12-05
2006-12-05
Jiang, S. Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S027230
Reexamination Certificate
active
07144871
ABSTRACT:
Disclosed are novel compounds that are partial and full A1adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.
REFERENCES:
patent: 6258793 (2001-07-01), Palle et al.
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6576619 (2003-06-01), Blackburn et al.
patent: 6576620 (2003-06-01), Belardinelli et al.
patent: 6605597 (2003-08-01), Zablocki et al.
patent: WO 99/67262 (1999-12-01), None
patent: WO 01/40799 (2002-07-01), None
patent: WO 02/70532 (2002-09-01), None
patent: WO03/070739 (2003-08-01), None
Dalpaiz et al. (I), “Characterization of Potential Adenosine A1Receptor Prodrugs of Adenosine Derivatives with Antiischemic Properties,”Acta Technologiae et Legis Medicamenti, 13(1), 49-57 (2002);Chemical Abstracts, 138, Abstr. No. 215195, HCAPlus No. 660483 (2002); only HCAPlus Abstract supplied.
Van Tilberg et al. (II), “5′ -O-Alkyl Ethers of N,2-Substituted Adenosine Derivatives: Partial Agonists for the Adenosine A1and A3Receptors,”Journal of Medicinal Chemistry, 44(18), 2966-2975 (Aug. 30, 2001).
Dalpaiz et al. (II), “Synthesis and Study of 5′-Ester Prodrugs of N6-Cyclopentyladenosine, a Selective A1Receptor Agonist,”Pharmaceutical Research, 18(4), 531-536 (2001).
Prashad et al., “Steric Effect of a Bulky Substituent at 5′-Position on the Regiospecificity of 2′- vs. 3′-O-Methylation of N6-Cyclohexyladenosine,”Nucleosides&Nucleotides, 13(4), 945-952 (1994);Chemical Abstracts, 122, Abstr. No. 81841, HCAPlus No. 14215 (1995); only HCAPlus Abstract supplied.
Maillard et al., “Adenosine Receptor Prodrugs: Synthesis and Biological Activity of Derivatives of Potent, A1-Selective Agonists,”Journal of Pharmaceutical Sciences, 83(1), 46-53 (Jan., 1994).
(W) Dhalla et al., “Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands,” Current Topics in Medicinal Chemistry, 3(4), 369-385 (2003).
Dhalla et al., “Pharmacology and Therapeutic Applications of A1Adenosine Receptor Ligands,”Current Topics in Medicinal Chemistry, 3(4), 369-385 (2003).
Elzein Elfatih
Ibrahim Prabha
Jiang Robert
Li Xiaofen
Morrison Christopher
Clarke Pauline Ann
Crane L. E.
CV Therapeutics Inc.
Hartrum J. Elin
Jiang S. Anna
LandOfFree
Partial and full agonists of A 1 adenosine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Partial and full agonists of A 1 adenosine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Partial and full agonists of A 1 adenosine receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695596